STOCKHOLM, June 25, 2024 /PRNewswire/ — Neonode Inc. (NASDAQ: NEON), announced today that its 2024 Annual Meeting of Stockholders (the “Annual Meeting”), which was reconvened to June 25, 2024, was called to order and again adjourned without any business being conducted due to a lack of the required quorum.
The Annual Meeting will reconvene on July 5, 2024 at 3:00 p.m. local time at Neonode’s principal executive office located at Karlavägen 100, 115 26 Stockholm, Sweden to provide its stockholders additional time to vote on the proposals described in the proxy statement filed with the Securities and Exchange Commission on April 26, 2024. No changes have been made in the proposals to be voted on by stockholders at the Annual Meeting.
The record date for determining stockholder eligibility to vote at the Annual Meeting will remain the close of business on April 22, 2024. Proxies previously submitted will be voted at the Annual Meeting unless properly revoked, and stockholders who have already submitted a proxy or otherwise voted need not take any action.
Neonode’s Board of Directors unanimously recommends that stockholders vote “FOR” all proposals and encourages all stockholders who have not already voted to do so immediately.
For more information or questions, please contact:
Interim President and Chief Executive Officer and Chief Financial Officer
Fredrik Nihlén
E-mail: fredrik.nihlen@neonode.com
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Neonode – Press Release (Annual Meeting Adjournment 2; June 2024) |
|
https://news.cision.com/neonode/i/neonode-reconvened-meeting-adjournment,c3314426 |
neonode-reconvened-meeting-adjournment |
SOURCE Neonode
Charlotte, North Carolina--(Newsfile Corp. - December 23, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE…
AUSTIN, TEXAS / ACCESSWIRE / December 23, 2024 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or…
Originally published in Quest Diagnostics' 2023 Corporate Responsibility ReportNORTHAMPTON, MA / ACCESSWIRE / December 23,…
Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage…
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…